PSA Test Valuable In Predicting Biopsy Need

A new Mayo Clinic study found the prostate-specific antigen test was accurate in predicting which men should have biopsies and which are likely to be diagnosed with low-risk prostate cancer, a news release said.

More than 600 men between the ages of 40 and 79 were prospectively followed since 1990. The study found men in their 40s and 50s with a baseline PSA at or above the median were much more likely to both undergo a biopsy and be diagnosed with low-risk prostate cancer.

Related Articles about Prostate Cancer:
Physicians Question Federal Panel's Recommendation on Prostate Screening Tests
Vitamin E Linked to Higher Risk of Prostate Cancer
Tool Determines Risk of Death of Prostate Cancer Patients After Radiation

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers